Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday. The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $533.00. The company’s shares closed ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

Vertex Pharmaceuticals posted a double-digit increase in its quarterly revenue thanks to strong sales for its cystic-fibrosis treatment. The biotechnology company on Monday reported a profit of $ ...